Aclarion, inc. announces adjournment of special meeting of stockholders

Broomfield, colo., feb. 28, 2025 (globe newswire) -- aclarion, inc. ("aclarion" or the "company") (nasdaq: acon) (nasdaq: aconw), a healthcare technology company that leverages magnetic resonance spectroscopy ("mrs"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its special meeting of stockholders (the “special meeting”) scheduled for february 28, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the company's definitive proxy statement for the special meeting, filed with the securities and exchange commission (the “sec”) on february 3, 2025.
ACON Ratings Summary
ACON Quant Ranking